 |
50 Diseases |  |
65 Trials |
|
65 Trials |  |
4287 News |  |
| «12...3637383940414243444546...4950» |
- | Zelboraf (vemurafenib) / Roche
Trial primary completion date, Combination therapy, Metastases: Vemurafenib and TIL Therapy for Metastatic Melanoma (clinicaltrials.gov) - Oct 11, 2018
P1/2, N=12, Active, not recruiting, Sponsor: Inge Marie Svane
Trial primary completion date: Aug 2018 --> Dec 2018
- | Journal: Update on hairy cell leukemia. (Pubmed Central) - Sep 28, 2018
Rituximab has limited activity as a single agent but achieves high complete remission rates without minimal residual disease when combined with purine analogues, albeit with chemotherapy-associated toxicity. Investigational nonchemotherapy options include moxetumomab pasudotox, which targets CD22; vemurafenib or dabrafenib, each of which targets the BRAF V600E protein; trametinib, which targets mitogen-activated protein kinase enzyme (MEK); and ibrutinib, which targets Bruton tyrosine kinase (BTK).
- | Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche, Tecentriq (atezolizumab) / Roche
Enrollment closed, PD(L)-1 Biomarker, Metastases: IMspire150: A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma (clinicaltrials.gov) - Sep 24, 2018
P3, N=513, Active, not recruiting, Sponsor: Hoffmann-La Roche
Investigational nonchemotherapy options include moxetumomab pasudotox, which targets CD22; vemurafenib or dabrafenib, each of which targets the BRAF V600E protein; trametinib, which targets mitogen-activated protein kinase enzyme (MEK); and ibrutinib, which targets Bruton tyrosine kinase (BTK). Recruiting --> Active, not recruiting
- | Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Metastases: Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib (clinicaltrials.gov) - Sep 19, 2018
P1/2, N=18, Terminated, Sponsor: Mohammed M Milhem
Recruiting --> Active, not recruiting N=38 --> 18 | Trial completion date: Jun 2020 --> Sep 2018 | Active, not recruiting --> Terminated | Trial primary completion date: Jun 2019 --> Jun 2018; Loss of funding
- | Xalkori (crizotinib) / Pfizer, Zelboraf (vemurafenib) / Roche
Enrollment change, Trial completion date, Combination therapy, Metastases: Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations (clinicaltrials.gov) - Sep 17, 2018
P1, N=183, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
N=38 --> 18 | Trial completion date: Jun 2020 --> Sep 2018 | Active, not recruiting --> Terminated | Trial primary completion date: Jun 2019 --> Jun 2018; Loss of funding N=46 --> 183 | Trial completion date: Feb 2021 --> Feb 2020
- | Zelboraf (vemurafenib) / Roche
Journal: Cutaneous wound healing through paradoxical MAPK activation by BRAF inhibitors. (Pubmed Central) - Sep 6, 2018
Here we show how the BRAF inhibitor vemurafenib accelerates skin wound healing by inducing the proliferation and migration of human keratinocytes through extracellular signal-regulated kinase (ERK) phosphorylation and cell cycle progression...The same dosing regimen of topical BRAF inhibitor does not increase the incidence of cutaneous squamous cell carcinomas in mice. Therefore, topical BRAF inhibitors may have clinical applications in accelerating the healing of skin wounds.
- | Phase classification, PD(L)-1 Biomarker: NeoACTIVATE: Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma (clinicaltrials.gov) - Sep 4, 2018
P2, N=30, Recruiting, Sponsor: Mayo Clinic
Therefore, topical BRAF inhibitors may have clinical applications in accelerating the healing of skin wounds. Phase classification: P1 --> P2
- | Zelboraf (vemurafenib) / Roche, Yervoy (ipilimumab) / Ono Pharma, BMS
Review, Journal, Adverse events: Direct costs associated with adverse events of systemic therapies for advanced melanoma: Systematic literature review. (Pubmed Central) - Aug 29, 2018
Costs for managing each type of AE associated with the treatment of advanced melanoma are substantial. Effective treatments with improved safety profiles may help reduce total AE management costs.
- | Zelboraf (vemurafenib) / Roche
Trial completion, Trial primary completion date, Metastases: A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma (clinicaltrials.gov) - Aug 22, 2018
P1, N=8, Completed, Sponsor: Abramson Cancer Center of the University of Pennsylvania
Effective treatments with improved safety profiles may help reduce total AE management costs. Active, not recruiting --> Completed | Trial primary completion date: Jan 2016 --> Jul 2016
- | Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche, Tecentriq (atezolizumab) / Roche
New P2 trial, PD(L)-1 Biomarker: Tricotel: A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases (clinicaltrials.gov) - Aug 10, 2018
P2, N=120, Not yet recruiting, Sponsor: Hoffmann-La Roche
- | Zelboraf (vemurafenib) / Roche
Clinical, Journal: Primary Cutaneous Small/Medium CD4+ T-CELL Lymphoproliferative Disorder Occurring in a Patient With Metastatic Melanoma. (Pubmed Central) - Aug 8, 2018
The immunostimulatory properties of IL-2 or vemurafenib may be responsible for the development of PC-SMTCL in our patient. Additionally, antigenic stimulation of the immune system by melanoma itself could contribute to clonal selection of lymphocytes.
- | Keytruda (pembrolizumab) / Merck (MSD), Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche
Trial completion date, Trial primary completion date, PD(L)-1 Biomarker, Metastases: Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma (clinicaltrials.gov) - Aug 2, 2018
P1, N=50, Recruiting, Sponsor: Yana Najjar
Additionally, antigenic stimulation of the immune system by melanoma itself could contribute to clonal selection of lymphocytes. Trial completion date: Oct 2018 --> Oct 2019 | Trial primary completion date: Jun 2018 --> Jun 2019
- | Clinical, Observational data, Journal: Melanocytic lesion evolution patterns with targeted therapies and immunotherapies for advanced metastatic melanoma: An observational study. (Pubmed Central) - Aug 1, 2018
The findings emphasise the importance of regular dermatological monitoring in specialised clinics for patients on anti-melanoma systemic therapy. Clinicians should expect changes in the global pigmentation of melanocytic lesions but be suspicious of lesions with structural changes.
- | Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche
Trial completion date, Metastases: A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma (clinicaltrials.gov) - Aug 1, 2018
P2, N=52, Active, not recruiting, Sponsor: Hoffmann-La Roche
Clinicians should expect changes in the global pigmentation of melanocytic lesions but be suspicious of lesions with structural changes. Trial completion date: Jul 2021 --> Jul 2019
- | Zelboraf (vemurafenib) / Roche
Enrollment closed: A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State (clinicaltrials.gov) - Jul 26, 2018
P1, N=32, Active, not recruiting, Sponsor: Genentech, Inc.
Trial completion date: Jul 2021 --> Jul 2019 Recruiting --> Active, not recruiting
- | Zelboraf (vemurafenib) / Roche
Clinical, Journal: Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E. (Pubmed Central) - Jul 4, 2018
No new safety signals were reported. Vemurafenib showed activity in patients with advanced melanoma with rarer BRAF mutations.
- | Zelboraf (vemurafenib) / Roche
Enrollment closed, Combination therapy, Metastases: Vemurafenib and TIL Therapy for Metastatic Melanoma (clinicaltrials.gov) - Jul 2, 2018
P1/2, N=12, Active, not recruiting, Sponsor: Inge Marie Svane
Vemurafenib showed activity in patients with advanced melanoma with rarer BRAF mutations. Recruiting --> Active, not recruiting
- | Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche
Trial completion date, Trial primary completion date, Metastases: Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib (clinicaltrials.gov) - Jun 26, 2018
P1/2, N=38, Active, not recruiting, Sponsor: Mohammed M Milhem
Recruiting --> Active, not recruiting Trial completion date: Jun 2019 --> Jun 2020 | Trial primary completion date: Jun 2018 --> Jun 2019
- || Enrollment open, PD(L)-1 Biomarker: NeoACTIVATE: Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma (clinicaltrials.gov) - Jun 26, 2018
P1, N=30, Recruiting, Sponsor: Mayo Clinic
Trial completion date: Jun 2019 --> Jun 2020 | Trial primary completion date: Jun 2018 --> Jun 2019 Not yet recruiting --> Recruiting
- | Zelboraf (vemurafenib) / Roche, XL888 / Exelixis, Merck (MSD)
Trial completion date: Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma (clinicaltrials.gov) - Jun 20, 2018
P1, N=21, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Not yet recruiting --> Recruiting Trial completion date: Feb 2019 --> Jun 2019
- ||| pacmilimab (CX-072) / CytomX
Enrollment change, Combination therapy, Monotherapy, Metastases: PROCLAIM-072 : PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas (clinicaltrials.gov) - Jun 15, 2018
P1/2, N=300, Recruiting, Sponsor: CytomX Therapeutics
Trial completion date: Feb 2019 --> Jun 2019 N=150 --> 300
- | New P1 trial, New P2 trial, PD(L)-1 Biomarker: NeoACTIVATE: Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma (clinicaltrials.gov) - Jun 11, 2018
P1, N=30, Not yet recruiting, Sponsor: Mayo Clinic
- | Opdivo (nivolumab) / Ono Pharma, BMS, Zelboraf (vemurafenib) / Roche
Clinical, Journal, PD(L)-1 Biomarker, IO biomarker: Exceptional Response with Immunotherapy in a Patient with Anaplastic Thyroid Cancer. (Pubmed Central) - Jun 9, 2018
N=150 --> 300 Programmed death-1 (PD-1)/PD-L1 immunotherapy has shown evidence of durable responses in certain malignancies such as melanoma, lung cancer, and renal cell carcinoma.PD-L1 positive tumors promote autoimmunity against the tumor; therefore, PD-1/PD-L1 blockade may be beneficial.Molecular profiling could possibly result in improved targeted therapy for certain malignancies.
- | Opdivo (nivolumab) / BMS, Braftovi (encorafenib) / Pfizer, Mektovi (binimetinib) / Pfizer
Enrollment open: Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma (clinicaltrials.gov) - Jun 6, 2018
P1, N=20, Recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Programmed death-1 (PD-1)/PD-L1 immunotherapy has shown evidence of durable responses in certain malignancies such as melanoma, lung cancer, and renal cell carcinoma.PD-L1 positive tumors promote autoimmunity against the tumor; therefore, PD-1/PD-L1 blockade may be beneficial.Molecular profiling could possibly result in improved targeted therapy for certain malignancies. Not yet recruiting --> Recruiting
- | Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche
New P2 trial, PD(L)-1 Biomarker: To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib. (clinicaltrials.gov) - Jun 3, 2018
P2, N=120, Not yet recruiting, Sponsor: Intergruppo Melanoma Italiano
- | Opdivo (nivolumab) / BMS, Braftovi (encorafenib) / Pfizer, Mektovi (binimetinib) / Pfizer
New P1 trial: Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma (clinicaltrials.gov) - Jun 2, 2018
P1, N=20, Not yet recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- || Trial completion date, Trial primary completion date, Tumor mutational burden, PD(L)-1 Biomarker: My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Jun 1, 2018
P2a, N=600, Recruiting, Sponsor: Genentech, Inc.
Not yet recruiting --> Recruiting Trial completion date: Aug 2019 --> Aug 2020 | Trial primary completion date: Aug 2019 --> Aug 2020
- ||| Enrollment change, Tumor mutational burden, BRCA Biomarker, MSi-H Biomarker, PARP Biomarker, PD(L)-1 Biomarker: TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (clinicaltrials.gov) - May 31, 2018
P2, N=1440, Recruiting, Sponsor: American Society of Clinical Oncology
Trial completion date: Aug 2019 --> Aug 2020 | Trial primary completion date: Aug 2019 --> Aug 2020 N=1060 --> 1440
- | Zelboraf (vemurafenib) / Roche
Preclinical, Journal: BRAF fusion as a novel mechanism of acquired resistance to vemurafenib in BRAF V600E mutant melanoma. (Pubmed Central) - May 13, 2018
We report acquisition of a BRAF fusion as a novel mechanism of acquired resistance to vemurafenib in a patient with melanoma harboring a BRAF(V600E) mutation. The acquisition and regression of clones harboring this fusion during the presence and absence of a BRAF inhibitor are consistent with rapidly evolving clonal dynamics in melanoma.
- | Proleukin (aldesleukin) / Clinigen, Novartis, Prometheus, Zelboraf (vemurafenib) / Roche
Clinical, P2 data, Journal, PD(L)-1 Biomarker, IO biomarker: A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma. (Pubmed Central) - May 4, 2018
P2
Given the efficacy of regimens targeting the PD-1 pathway, strategies combining these regimens with BRAF-targeted therapy are currently underway, and the role of combination vemurafenib and HD-IL-2 is uncertain. Trial Registration: Clinical trial information: NCT01754376; https://clinicaltrials.gov/show/NCT01754376.
- | Zelboraf (vemurafenib) / Roche
Journal: CRAF R391W is a melanoma driver oncogene. (Pubmed Central) - May 3, 2018
This cell line demonstrated a signaling profile similar to BRAF-mutants, but lacked sensitivity to the BRAF inhibitor vemurafenib...MAP kinase inducing activity was dependent on CRAF dimerization. Thus, CRAF is a bona fide alternative oncogene for BRAF/NRAS/GNAQ/GNA11 wild type melanomas.
- || Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche
Trial primary completion date, Metastases: REPOSIT: Vemurafenib Plus Cobimetinib in Metastatic Melanoma (clinicaltrials.gov) - May 2, 2018
P2, N=90, Recruiting, Sponsor: Netherlands Working Group on Immunotherapy of Oncology
Thus, CRAF is a bona fide alternative oncogene for BRAF/NRAS/GNAQ/GNA11 wild type melanomas. Trial primary completion date: Dec 2017 --> Dec 2018
- | Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche, Tecentriq (atezolizumab) / Roche
Trial completion date, Trial primary completion date, PD(L)-1 Biomarker, IO biomarker, Metastases: ImmunoCobiVem: Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma (clinicaltrials.gov) - Apr 27, 2018
P2, N=176, Recruiting, Sponsor: University Hospital, Essen
Trial primary completion date: Dec 2017 --> Dec 2018 Trial completion date: Jun 2020 --> Dec 2021 | Trial primary completion date: Mar 2020 --> Sep 2021
- |||||| Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche, Tecentriq (atezolizumab) / Roche
Enrollment open, PD(L)-1 Biomarker, Metastases: IMspire150: A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma (clinicaltrials.gov) - Apr 18, 2018
P3, N=500, Recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Jun 2020 --> Dec 2021 | Trial primary completion date: Mar 2020 --> Sep 2021 Active, not recruiting --> Recruiting
- ||||| New P2 trial, PARP Biomarker, PD(L)-1 Biomarker: CUPISCO: A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site (clinicaltrials.gov) - Apr 12, 2018
P2, N=790, Recruiting, Sponsor: Hoffmann-La Roche
- | Zelboraf (vemurafenib) / Roche
Biomarker, Trial completion date, Trial primary completion date, Metastases: Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) (clinicaltrials.gov) - Apr 12, 2018
P2, N=49, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Recruiting Trial completion date: Apr 2022 --> Dec 2023 | Trial primary completion date: Apr 2022 --> Dec 2023
- | Biomarker, Trial completion date, Trial primary completion date, BRCA Biomarker, PARP Biomarker, Metastases: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) (clinicaltrials.gov) - Apr 12, 2018
P2, N=1500, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Apr 2022 --> Dec 2023 | Trial primary completion date: Apr 2022 --> Dec 2023 Trial completion date: Dec 2021 --> Sep 2027 | Trial primary completion date: Dec 2021 --> Sep 2027
- | Biomarker, Trial suspension, MSi-H Biomarker, PD(L)-1 Biomarker: MODUL: A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Apr 9, 2018
P2, N=1400, Suspended, Sponsor: Hoffmann-La Roche
Trial completion date: Dec 2021 --> Sep 2027 | Trial primary completion date: Dec 2021 --> Sep 2027 Recruiting --> Suspended
- ||||| Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche, Tecentriq (atezolizumab) / Roche
Enrollment closed, PD(L)-1 Biomarker, Metastases: IMspire150: A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma (clinicaltrials.gov) - Apr 5, 2018
P3, N=500, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Suspended Recruiting --> Active, not recruiting
- | Zelboraf (vemurafenib) / Roche
Clinical, Journal, Combination therapy: Salmonella typhimurium A1-R targeting of a chemotherapy resistant BRAF-V600E melanoma in a patient-derived orthotopic xenograft (PDOX) model is enhanced in combination with either vemurafenib-temozlomide. (Pubmed Central) - Apr 5, 2018
typhimurium A1-R + TEM: p <0.01, S. typhimurium A1-R + VEM: p <0.01). In conclusion, chemotherapy drugs promoted targeting of S. typhimurium A1-R of melanoma, thereby enhancing efficacy against the melanoma PDOX.
- | PLX8394 / Novellus, Zelboraf (vemurafenib) / Roche
Preclinical, Journal: Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer. (Pubmed Central) - Apr 3, 2018
We further show that acquired PLX8394 resistance occurs via EGFR-mediated RAS-mTOR signaling and is prevented by upfront combination therapy with PLX8394 and either an EGFR or mTOR inhibitor. Our study provides a biological rationale and potential polytherapy strategy to aid the deployment of PLX8394 in lung cancer patients.
- | Clinical, Journal, Adverse events: Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma. (Pubmed Central) - Apr 3, 2018
Prompt identification and an understanding of which adverse events are most likely BRAF or MEK inhibitor associated provide a rationale for appropriate therapy adjustments. Practical recommendations derived from clinical experience are provided for management of key drug-related toxicities.
- | Torisel (temsirolimus) / Pfizer, Zelboraf (vemurafenib) / Roche
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer (clinicaltrials.gov) - Apr 3, 2018
P1, N=114, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Practical recommendations derived from clinical experience are provided for management of key drug-related toxicities. Trial completion date: Dec 2018 --> Dec 2020 | Trial primary completion date: Dec 2018 --> Dec 2019
- | Zelboraf (vemurafenib) / Roche
Trial completion date, Trial primary completion date: Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma (clinicaltrials.gov) - Mar 30, 2018
P2, N=17, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Trial completion date: Dec 2018 --> Dec 2020 | Trial primary completion date: Dec 2018 --> Dec 2019 Trial completion date: Aug 2019 --> Dec 2019 | Trial primary completion date: Aug 2018 --> Dec 2018
- | Xalkori (crizotinib) / Pfizer, Zelboraf (vemurafenib) / Roche
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations (clinicaltrials.gov) - Mar 23, 2018
P1, N=183, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Aug 2019 --> Dec 2019 | Trial primary completion date: Aug 2018 --> Dec 2018 Trial completion date: Feb 2019 --> Feb 2021 | Trial primary completion date: Feb 2019 --> Feb 2020
- | Zelboraf (vemurafenib) / Roche
Journal: Response of relapsed central nervous system hairy cell leukemia to vemurafenib. (Pubmed Central) - Mar 22, 2018
Trial completion date: Feb 2019 --> Feb 2021 | Trial primary completion date: Feb 2019 --> Feb 2020 No abstract available
- ||| Braftovi (encorafenib) / Pfizer, Mektovi (binimetinib) / Pfizer
Trial completion date, Monotherapy, Metastases: COLUMBUS: Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma (clinicaltrials.gov) - Mar 21, 2018
P3, N=921, Active, not recruiting, Sponsor: Array BioPharma
No abstract available Trial completion date: Mar 2018 --> Mar 2019
- | Zelboraf (vemurafenib) / Roche
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Vemurafenib and TIL Therapy for Metastatic Melanoma (clinicaltrials.gov) - Mar 19, 2018
P1/2, N=12, Recruiting, Sponsor: Inge Marie Svane
Trial completion date: Mar 2018 --> Mar 2019 Trial completion date: Nov 2017 --> Aug 2020 | Trial primary completion date: Nov 2016 --> Aug 2018
- | Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche
Enrollment closed, Metastases: Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib (clinicaltrials.gov) - Mar 16, 2018
P1/2, N=38, Active, not recruiting, Sponsor: Mohammed M Milhem
Trial completion date: Nov 2017 --> Aug 2020 | Trial primary completion date: Nov 2016 --> Aug 2018 Recruiting --> Active, not recruiting
- || Biomarker, Trial completion date, Trial primary completion date, MSi-H Biomarker, PD(L)-1 Biomarker: MODUL: A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Mar 16, 2018
P2, N=1400, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Trial completion date: Oct 2020 --> Dec 2021 | Trial primary completion date: May 2017 --> May 2019